DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

Statistics in Biopharmaceutical Research, published by Taylor & Francis Inc, is a premier journal that occupies a crucial space in the realms of Pharmaceutical Science and Statistics and Probability. With a robust impact factor affirmed by its Q1 rankings in both categories, the journal stands as a beacon for innovative statistical methodologies and their applications in biopharmaceutical research. Researchers and professionals will find a rich repository of high-quality articles that address contemporary challenges in drug development, clinical trials, and regulatory frameworks. Since its inception in 2011, the journal has continued to foster interdisciplinary collaboration, making significant strides towards enhancing statistical practice in biomedicine. With a commitment to academic rigor and practical relevance, Statistics in Biopharmaceutical Research is an essential resource for anyone looking to advance their understanding and application of statistical techniques in the pharmaceutical industry.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.

Pharmaceutical Patent Analyst, published by Taylor & Francis Ltd, is a premier journal dedicated to the evolving fields of pharmaceutical science and patent law. Established in 2012, this journal provides a rigorous platform for scholarly articles, analytical studies, and insightful reviews that delve into the intersection of drug discovery, pharmaceutical innovation, and intellectual property rights. With a Q2 category ranking in Pharmaceutical Science and Q3 rankings in both Drug Discovery and Medicine (miscellaneous), it is recognized for its impactful contributions to the academic community and industry professionals alike. The journal aims to enhance the understanding of patent strategies, explore emerging pharmaceutical technologies, and foster dialogue on regulatory challenges, ultimately facilitating innovation in drug development. Although it does not currently offer open access, its comprehensive and high-quality content remains essential for researchers, professionals, and students pursuing excellence in pharmaceutical research and patent analysis.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.